A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine
- PMID: 32566636
- PMCID: PMC7290560
- DOI: 10.21037/atm-20-1855
A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine
Abstract
Biomarkers to guide antibiotic treatment decisions have been proposed as an effective way to enhancing a more appropriate use of antibiotics. As a biomarker, procalcitonin (PCT) has been found to have good specificity to distinguish bacterial from non-bacterial inflammations. Decisions regarding antibiotic use in an individual patient are complex and should be based on the pre-test probability for bacterial infection, the severity of presentation and the results of PCT serum concentration. In the context of a high pre-test probability for bacterial infections and/or a high-risk patient with sepsis, monitoring of PCT over time helps to track the resolution of infection and decisions regarding early stop of antibiotic treatment. As outlined by the Evidence Based Laboratory Medicine (EBLM), not only the pre-test probability but also the positive likelihood ratio influence the performance of a test do be really diagnostic. This aspect should be taken into account in the interpretation of the results of clinical trials evaluating the performance of PCT in guiding antibiotic therapy.
Keywords: Evidence Based Laboratory Medicine (EBLM); Procalcitonin (PCT); antibiotic therapy.
2020 Annals of Translational Medicine. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-1855). The series “Advances in Laboratory Tests for Infectious Diseases” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.
Similar articles
-
How to best use procalcitonin to diagnose infections and manage antibiotic treatment.Clin Chem Lab Med. 2022 Nov 2;61(5):822-828. doi: 10.1515/cclm-2022-1072. Print 2023 Apr 25. Clin Chem Lab Med. 2022. PMID: 36317790 Review.
-
How to: implement procalcitonin testing in my practice.Clin Microbiol Infect. 2019 Oct;25(10):1226-1230. doi: 10.1016/j.cmi.2018.12.028. Epub 2019 Jan 4. Clin Microbiol Infect. 2019. PMID: 30616016
-
The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?Surg Infect (Larchmt). 2013 Dec;14(6):489-511. doi: 10.1089/sur.2012.028. Epub 2013 Nov 25. Surg Infect (Larchmt). 2013. PMID: 24274059 Review.
-
Procalcitonin to guide antibiotic decision making.Curr Opin Infect Dis. 2019 Apr;32(2):130-135. doi: 10.1097/QCO.0000000000000522. Curr Opin Infect Dis. 2019. PMID: 30648993 Review.
-
Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy.Breathe (Sheff). 2019 Dec;15(4):296-304. doi: 10.1183/20734735.0258-2019. Breathe (Sheff). 2019. PMID: 31803264 Free PMC article. Review.
Cited by
-
The Novel Coronavirus and Inflammation.Adv Exp Med Biol. 2021;1321:127-138. doi: 10.1007/978-3-030-59261-5_11. Adv Exp Med Biol. 2021. PMID: 33656719 Review.
-
Comparison of outcome between blood culture positive and negative infective endocarditis patients undergoing cardiac surgery.J Cardiothorac Surg. 2021 May 27;16(1):147. doi: 10.1186/s13019-021-01532-9. J Cardiothorac Surg. 2021. PMID: 34044847 Free PMC article.
-
Early Low Level of Procalcitonin Is Associated with a Favorable Outcome in a Case of a Surviving Patient with 80% Body Surface Area Thermal Burn.Am J Case Rep. 2021 Nov 26;22:e934052. doi: 10.12659/AJCR.934052. Am J Case Rep. 2021. PMID: 35642541 Free PMC article.
-
Proposal of COVID-19 Clinical Risk Score for the management of suspected COVID-19 cases: a case control study.BMC Infect Dis. 2020 Nov 18;20(1):858. doi: 10.1186/s12879-020-05604-4. BMC Infect Dis. 2020. PMID: 33208116 Free PMC article.
-
Procalcitonin as an Early Marker of Colorectal Anastomotic Leakage in Postoperative Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.Cureus. 2024 Oct 1;16(10):e70647. doi: 10.7759/cureus.70647. eCollection 2024 Oct. Cureus. 2024. PMID: 39483587 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials